OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Pant on the RAGNAR Trial of Erdafitinib in Biliary Tract Cancer

January 26th 2023

Shubham Pant, MD, discusses the rationale, trial design, and key efficacy and safety data from an expansion cohort of the phase 2 RAGNAR trial in biliary tract cancers.

Dr. Rotroff on Biomarkers Associated With the Risk of Peripheral Neuropathy in Breast Cancer

January 25th 2023

Daniel Rotroff, PhD, discusses the investigation of biomarkers that could help identify patients with breast cancer who are at risk for developing chemotherapy-induced peripheral neuropathy.

Dr. Hecht on the Symptoms and Diagnosis of ESCC

January 25th 2023

J. Randolph (Randy) Hecht, MD, discusses the common symptoms of esophageal squamous cell carcinoma.

Dr. Chmielowski on the Potential Role of RP1 in Melanoma after Anti–PD-1 Failure

January 25th 2023

Bartosz Chmielowski, MD, discusses the potential role of vusolimogene oderparepvec in the treatment of patients with melanoma who failed prior treatment with an anti–PD-1 therapy.

Dr. Daver on the Use of ADCs in BPDCN

January 25th 2023

Naval Daver, MD, discusses the use of antibody-drug conjugates (ADC) in the treatment of patients with blastic plasmacytoid dendritic cell neoplasm.

Dr. Pishvaian on the Implications of the RATIONALE-306 Trial in ESCC

January 25th 2023

Michael Jon Pishvaian, MD, PhD, discusses the clinical implications of the phase 3 RATIONALE 306 trial and the adverse effects associated with immunotherapy in patients with advanced esophageal squamous cell carcinoma.

Dr. Hunter on the Role of 18F-FES-PET Imaging in Triple-Positive Breast Cancer

January 25th 2023

Natasha B Hunter, MD, discusses the utility of 18F-Fluoroestradiol PET imaging for patients with estrogen receptor–positive and HER2-positive breast cancer.

Dr. Giralt on Long-Term Outcomes with HSCT in Multiple Myeloma

January 25th 2023

Sergio A. Giralt, MD, discusses long-term outcomes with hematopoietic stem cell transplant in multiple myeloma

Dr. Vicini on the Potential Utility of the DCISionRT Test in HER2+ DCIS of the Breast

January 25th 2023

Frank A. Vicini, MD, discusses the potential utility of using the DCISionRT test to determine treatment benefit in the phase 3 NRG-NSABP-B43 trial in HER2-positive ductal carcinoma in situ of the breast.

Dr. Stanton on Improving Responses to Immunotherapy in Early-Stage HR+ Breast Cancer

January 25th 2023

Sasha Stanton, MD, discusses efforts to improve the responses to immunotherapy regimens in early-stage hormone receptor–positive breast cancer.

Dr. Flinn on the FDA Approval of Zanubrutinib in CLL/SLL

January 25th 2023

Ian Flinn, MD, PhD, discusses the significance of the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Alldredge on Managing AEs With PARP Inhibitors in Ovarian Cancer

January 24th 2023

Jill Alldredge, MD, discusses the toxicities associated with PARP inhibition and the management of those adverse effects in patients with ovarian cancer.

Dr. Iyengar on the Benefit of Trastuzumab Deruxtecan in Metastatic HER2+ Breast Cancer After T-DM1

January 24th 2023

Neil M. Iyengar, MD, discusses the expanding investigation and role of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer.

Dr. Kopetz on Safety Lead-in Data from the BREAKWATER Trial in BRAF V600E–Mutant mCRC

January 22nd 2023

Scott Kopetz, MD, PhD, FACP, discusses the safety lead-in data from the phase 3 BREAKWATER trial in patients with BRBRAF V600E–mutant metastatic colorectal cancer.

Dr. Wainberg on Liposomal Irinotecan/NALIRIFOX vs Nab-paclitaxel/Gemcitabine in PDAC

January 22nd 2023

Zev A. Wainberg, MD, discusses the evaluation of liposomal irinotecan plus 5-fluorouracil leucovorin, and oxaliplatin vs nab-paclitaxel plus gemcitabine in the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Dr. Tabernero on the Efficacy of Bevacizumab Plus TAS-102 in Refractory mCRC

January 21st 2023

Josep Tabernero, MD, PhD, discusses findings from the phase 3 SUNLIGHT trial investigating the combination of bevacizumab plus trifluridine/tipiracil vs TAS-102 alone in patients with refractory metastatic colorectal cancer.

Dr. Dawson on the Addition of SBRT to Sorafenib in Locally Advanced HCC

January 21st 2023

Laura Dawson, MD, FRCPC, discusses results from the phase 3 NRG/RTOG 1112 trial of stereotactic body radiation therapy plus sorafenib compared with sorafenib alone in patients with locally advanced hepatocellular carcinoma.

Dr. Chari on Avenues for Future Research in Newly Diagnosed Multiple Myeloma

January 20th 2023

Ajay Chari, MD, discusses several avenues for future study in newly diagnosed multiple myeloma.

Dr. Fecteau on Salvage Therapy for Recurrent Prostate Cancer

January 20th 2023

Ryan Fecteau, MD, PhD, discusses the navigation of salvage treatment options for patients experiencing isolated prostate cancer recurrence.

Dr. Shitara on Zolbetuximab Plus mFOLFOX6 in CLDN18.2+, HER2– Gastric/GEJ Adenocarcinoma

January 20th 2023

Kohei Shitara, MD, discusses the evaluation of the combination of zolbetuximab plus mFOLFOX6 in patients with CLDN18.2–positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.